The COVID-19 pandemic and the use of MS disease-modifying therapies
Author:
Publisher
Elsevier BV
Subject
Clinical Neurology,Neurology,General Medicine
Reference27 articles.
1. The proximal origin of SARS-CoV-2;Andersen;Nat. Med.,2020
2. Acute and persistent infection of human neural cell lines by human coronavirus OC43;Arbour;J. Virol.,1999
3. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study;Cook;Mult. Scler.,2011
4. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management;Epstein;Open Forum Infect. Dis.,2018
5. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients;Fine;Clin. Infect. Dis.,2013
Cited by 155 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Era of COVID-19 in Multiple Sclerosis Care;Neurologic Clinics;2024-02
2. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022;Multiple Sclerosis Journal;2024-01-21
3. Flu-like syndrome due to interferon-beta injections does not increase anxiety, depression, and lost working days in multiple sclerosis patients during the Sars-CoV-2 pandemic;Clinical Neurology and Neurosurgery;2023-09
4. Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs;Multiple Sclerosis and Related Disorders;2023-09
5. The Impact of Body Mass Index on the Antibody Titer after Astra Zeneca Vaccination at UTA’45 Vaccine Center;Research Journal of Pharmacy and Technology;2023-06-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3